Results from the company’s Phase I trial found its prodrug, SPT-300, was well tolerated, opening the doors to a Phase IIb trial.

PureTech Health has cleared an early hurdle in its pursuit of Sage Therapeutics, linking its oral prodrug of allopregnanolone to a nine-fold increase in the blood levels achieved by the unmodified molecule. Based on the data, the company is forging ahead with a view to starting a phase 1b/2a clinical trial next year.